Neoplasms, Plasma Cell: all 2,314 studies
Page 13 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- Mass Accumulation Rate (MAR) as a Predictive Biomarker in Multiple MyelomaTerminatedNCT03777410
- Vascular Functions in Myeloma Patients During Anti-tumor TherapyStatus unknownNCT03776331
- A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory AgentCompletedNCT03768960Phase 4
- A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple MyelomaStatus unknownNCT03767751Phase 1/2
- Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple MyelomaStatus unknownNCT03767725Phase 1
- Multiple Myeloma Trial of Orally Administered Salmonella Based Survivin VaccineCompletedNCT03762291Phase 1
- Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple MyelomaActive, not recruitingNCT03756896Phase 2
- Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic LeukemiaTerminatedNCT03755154Phase 1
- Efficacy and Safety Evaluation of BCMA-UCARTSuspendedNCT03752541Not applicable
- A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple MyelomaStatus unknownNCT03751293Phase 1
- Safety and Efficacy of Daratumumab in Combination With Ixazomib and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaStatus unknownNCT03746652Phase 2
- Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
- Evaluation of Pharmacokinetics, Safety, and Preliminary Efficacy of Isatuximab in Chinese Patients With Relapsed and/or Refractory Multiple MyelomaCompletedNCT03733717Phase 1
- Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM PatientsTerminatedNCT03733691Phase 2
- Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
- Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple MyelomaStatus unknownNCT03720041Phase 3
- Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03716856Phase 1
- Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple MyelomaStatus unknownNCT03711864Phase 1
- A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple MyelomaTerminatedNCT03710915Phase 1
- Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MMStatus unknownNCT03706547Phase 1
- Place of the Hevylite Test in the Evaluation of MRD in MyelomaStatus unknownNCT03702088
- Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT03701321Phase 1/2
- Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple MyelomaCompletedNCT03700450Phase 2
- Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple MyelomaStatus unknownNCT03697655Phase 2
- A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT03697629Phase 2
- Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple MyelomaActive, not recruitingNCT03695744Phase 2
- IPD in RRMM Characterized with Genomic Abnormalities of Adverse PrognosticTerminatedNCT03683277Phase 2
- LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple MyelomaStatus unknownNCT03674463Phase 1
- CAR-T Re-treatment for Refractory/Relapsed Multiple MyelomaStatus unknownNCT03672253Phase 1
- Safety and Efficacy Assessments of Osalmid in Multiple MyelomaStatus unknownNCT03670173Phase 1/2
- Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple MyelomaStatus unknownNCT03669445Phase 2
- BCMA-CAR-T in Relapsed/Refractory Multiple MyelomaStatus unknownNCT03664661Phase 1
- BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple MyelomaStatus unknownNCT03661554Early Phase 1
- Postmarketing Study of Empliciti in Korean Patients With Multiple MyelomaWithdrawnNCT03660072
- Safety and Efficacy of ABI-009 (Nab-rapamycin) in Combination With Pomalidomide and Dexamethasone for Relapsed and Refractory Multiple MyelomaWithdrawnNCT03657420Phase 1
- MMRF CureCloud Research InitiativeTerminatedNCT03657251
- A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT03650491Phase 1
- Myeloma Treatment in Real LifeCompletedNCT03638232
- Pneumococcal Vaccination of Multiple Myeloma Patients on Novel AgentsCompletedNCT03619252Phase 4
- Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma PatientsStatus unknownNCT03618602Phase 1
- MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?TerminatedNCT03618212
- A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell TransplantationWithdrawnNCT03608501Phase 2
- A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI MalignanciesStatus unknownNCT03607643Phase 1/2
- An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma PatientsActive, not recruitingNCT03606577Phase 2
- Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple MyelomaCompletedNCT03605719Phase 1
- Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MMStatus unknownNCT03605056Phase 2
- A Study of the First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in SpainCompletedNCT03602755
- Pomalidomide/Cyclophosphamide/Dexamethasone in Relapse Refractory Myeloma: Safety Profile in MexicansStatus unknownNCT03601624Phase 2
- Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering MyelomaWithdrawnNCT03591614Early Phase 1
- Machine Learning in Myeloma ResponseStatus unknownNCT03574454Not applicable
- A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell ReinfusionStatus unknownNCT03570983Phase 2
- Study of BCMA CAR-T in Multiple MyelomaStatus unknownNCT03559764Early Phase 1
- A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.Active, not recruitingNCT03539744Phase 3
- Quality of Life in Patients With Multiple Myeloma-validation StudyTerminatedNCT03537222
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLLCompletedNCT03524235Phase 1
- Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple MyelomaTerminatedNCT03520985Phase 2
- Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi TreatmentStatus unknownNCT03515915
- Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell TransplantationCompletedNCT03508765Not applicable
- TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaWithdrawnNCT03506802Phase 1
- BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple MyelomaTerminatedNCT03502577Phase 1
- Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple MyelomaActive, not recruitingNCT03500445Phase 2
- Cost-Utility Analysis Hospital Versus Home in Multiple MyelomaCompletedNCT03493737
- Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple MyelomaWithdrawnNCT03492268Not applicable
- Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT03492138Phase 1/2
- MEDI2228 in Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT03489525Phase 1
- Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple MyelomaTerminatedNCT03486067Phase 1
- Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03477643
- Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple MyelomaStatus unknownNCT03475628Phase 2
- CAR-T Cells Therapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT03473496Not applicable
- Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma PatientsCompletedNCT03464916Phase 1
- Study Evaluating AMG 424 in Subjects With Multiple MyelomaTerminatedNCT03445663Phase 1
- Chemotherapy and G-CSF for MobilizationCompletedNCT03442673Phase 2
- Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and LymphomaStatus unknownNCT03436342Early Phase 1
- Monitoring of Deep of Response During Lenalidomide Maintenance in MM Patients Achieving at Least Very Good Partial Response (MRD)CompletedNCT03433365
- Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple MyelomaActive, not recruitingNCT03428373Phase 2/3
- Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in PatientsCompletedNCT03409692
- Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) PatientsCompletedNCT03406091
- Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.Status unknownNCT03405571
- Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for TransplantationCompletedNCT03402295Phase 3
- Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple MyelomaCompletedNCT03399539Phase 1
- Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous GraftWithdrawnNCT03393273Phase 2
- Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCTStatus unknownNCT03385096Phase 2/3
- Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple MyelomaStatus unknownNCT03380039Not applicable
- A Safety Study of SGN-CD48A in Patients With Multiple MyelomaTerminatedNCT03379584Phase 1
- Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma PatientsActive, not recruitingNCT03376672Phase 2
- Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide DexamethasoneCompletedNCT03375567Not applicable
- Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life ConditionsCompletedNCT03353545
- Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple MyelomaStatus unknownNCT03336073Phase 2
- Study of Personalized Melphalan Dosing in the Setting of Autologous TransplantWithdrawnNCT03328936Phase 2
- Study of BCMA CAR-T in Multiple MyelomaStatus unknownNCT03322735Phase 1/2
- Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.Active, not recruitingNCT03314636Phase 2
- Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple MyelomaCompletedNCT03311828Phase 1
- Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple MyelomaCompletedNCT03309111Phase 1
- ASCT With Nivolumab in Patients With Multiple MyelomaActive, not recruitingNCT03292263Phase 1/2
- Aggressive Smoldering Curative Approach Evaluating Novel Therapies and TransplantActive, not recruitingNCT03289299Phase 2
- A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT03288480Phase 1
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell TransplantationCompletedNCT03276481
- Study of bb21217 in Multiple MyelomaCompletedNCT03274219Phase 1